Story perspectives

J&J to Acquire Firefly Bio for $1 B, Adding KRAS Platform

6/8/2026

Summary

J&J Acquires Firefly

Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash.
The acquisition adds Firefly’s Firelink™ degrader antibody conjugate (DAC) platform targeting KRAS-driven solid tumors.
Executive Vice President John Reed said the platform could overcome limitations of current KRAS-driven cancer therapies.
Both boards approved the deal, which is slated to close later this year pending regulatory approvals and integration of Firefly’s preclinical candidates with J&J’s antibody engineering.

Summary

Firefly Secures Funding

Firefly Bio, co-founded by Nobel laureate Carolyn Bertozzi, secured $94 million in 2024 financing.
Its partnership with Tango Therapeutics produced a 92% response in a twelve-patient KRAS-targeted study.
KRAS mutations occur in nearly a quarter of cancers, with G12D the most frequent variant.
Johnson & Johnson and Jacobio Pharma advanced the oral KRAS G12C inhibitor glecirasib to phase 3, while Arvinas moved ARV-806 to phase 1 and Astellas halted ASP4396 after phase 1.

Summary

J&J Acquires Ambrx

J&J paid $2 billion in January 2026 to acquire Ambrx Biopharma for the experimental prostate cancer candidate JNJ-8177.
J&J seeks to offset falling Stelara revenue as the drug now faces biosimilar competition.
Darzalex, which earned $4 billion in Q1 2026, may soon lose patent protection.
The deal marks J&J’s second ADC-related acquisition since early 2024 and coincides with Firefly Bio’s nearly $100 million raise for its degrader-antibody conjugate platform.

History

Historical Context

Roche, the Basel-based pharma giant, completed a $46.8 billion purchase of Genentech in March 2009, fully integrating the U.S. biotech that had launched trastuzumab (1998) and bevacizumab (2004). The deal cemented Roche’s position as a leading oncology player and continued a decades-long pattern of large-scale acquisitions that reshape cancer drug development through the 2020s.

1 of 4

J&J Acquires Firefly

Johnson & Johnson agreed to buy Firefly Bio for $1 billion in cash.
The acquisition adds Firefly’s Firelink™ degrader antibody conjugate (DAC) platform targeting KRAS-driven solid tumors.
Executive Vice President John Reed said the platform could overcome limitations of current KRAS-driven cancer therapies.
Both boards approved the deal, which is slated to close later this year pending regulatory approvals and integration of Firefly’s preclinical candidates with J&J’s antibody engineering.

1 / 4